Acurx Pharmaceuticals (ACXP) Change in Receivables (2024 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Change in Receivables came in at $7896.0 in Q1 2026, up 115.44% YoY from $3665.0 in Q1 2025, and down 3.81% on a QoQ basis from $8209.0 in Q4 2025.
Acurx Pharmaceuticals (ACXP) Change in Receivables (2024 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 3 years of Change in Receivables data on file, last reported at $7896.0 in Q1 2026.
- Quarterly Change in Receivables rose 115.44% year-over-year to $7896.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56313.0 (changed N/A YoY) and the FY2025 annual result came in at -$2710.0, up 96.53% from the prior year.
- Change in Receivables fell to $7896.0 in Q1 2026, from $8209.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $51127.0 in Q2 2024 to a low of -$129159.0 in Q1 2024.
- A 3-year average of -$9105.8 and a median of $8052.5 in 2025 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 117.75% in 2025, down 21.36% in 2025.
- Tracing ACXP's Change in Receivables over 3 years: stood at -$46246.0 in 2024, then jumped by 117.75% to $8209.0 in 2025, then declined by 3.81% to $7896.0 in 2026.
- The last three Change in Receivables figures came in at $7896.0 (Q1 2026), $8209.0 (Q4 2025), and $40208.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 31.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 37.16 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 94.29 Mn |
| 10 | Acurx Pharmaceuticals | 6.18 Mn | 6.18 Mn | - | 38,994.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38,994.00 |
| Jun 30, 2026 | 38,994.00 |
| Mar 31, 2026 | 7,896.00 |
| Mar 31, 2026 | 7,896.00 |
| Dec 31, 2025 | 8,209.00 |
| Dec 31, 2025 | 8,209.00 |
| Jun 30, 2025 | 40,208.00 |
| Jun 30, 2025 | 40,208.00 |
| Mar 31, 2025 | -51,127.00 |
| Mar 31, 2025 | -51,127.00 |
| Dec 31, 2024 | -46,246.00 |
| Dec 31, 2024 | -46,246.00 |
| Sep 30, 2024 | 46,246.00 |
| Sep 30, 2024 | 46,246.00 |
| Jun 30, 2024 | 51,127.00 |
| Jun 30, 2024 | 51,127.00 |
| Mar 31, 2024 | -129,159.00 |
| Mar 31, 2024 | -129,159.00 |